IPR matters

Allergan has been particularly aggressive in trying to skirt the IPR system. In September, it took the unprecedented step of transferring patents protecting its prescription eyedrop, Restasis, to the Saint Regis Mohawks. The tribe — which received a $13.5m fee and up to $15m in annual royalties — then claimed it had sovereign immunity from intellectual property challenges launched through IPR. 

Pharma industry faces hypocrisy charge over patents

As I fond of repeating, Martin Wolf of the FT argued that Pharma may soon be shown the same contempt that many now feel towards the Banks.